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Abstract
Objectives: The Trp
620 allotype of PTPN22 confers susceptibility to rheumatoid arthritis (RA) and certain other classical
autoimmune diseases. There has been a report of other variants within the PTPN22 locus that alter risk of RA; protective
haplotype ‘5’, haplotype group ‘6–10’ and susceptibility haplotype ‘4’, suggesting the possibility of other PTPN22 variants
involved in the pathogenesis of RA independent of R620W (rs2476601). Our aim was to further investigate this possibility.
Methods: A total of 4,460 RA cases and 4,481 controls, all European, were analysed. Single nucleotide polymorphisms
rs3789607, rs12144309, rs3811021 and rs12566340 were genotyped over New Zealand (NZ) and UK samples. Publically-
available Wellcome Trust Case Control Consortium (WTCCC) genotype data were used.
Results: The protective effect of haplotype 5 was confirmed (rs3789607; (OR=0.91, P=0.016), and a second protective effect
(possibly of haplotype 6) was observed (rs12144309; OR=0.90, P=0.021). The previously reported susceptibility effect of
haplotype 4 was not replicated; instead a protective effect was observed (rs3811021; OR=0.85, P=1.4610
25). Haplotypes
defined by rs3789607, rs12144309 and rs3811021 coalesced with the major allele of rs12566340 within the adjacent BFK (B-
cell lymphoma 2 (BCL2) family kin) gene. We, therefore, tested rs12566340 for association with RA conditional on rs2476601;
there was no evidence for an independent effect at rs12566340 (P=0.76). Similarly, there was no evidence for an
independent effect at rs12566340 in type 1 diabetes (P=0.85).
Conclusions: We have no evidence for a common variant additional to rs2476601 within the PTPN22 locus that influences
the risk of RA. Arg620Trp is almost certainly the single common causal variant.
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Introduction
Genome-wide association (GWA) scans have emphasised the
importance of the PTPN22 gene, encoding the phosphatase LYP,
in susceptibility to rheumatoid arthritis (RA) in European and
European-ancestry populations, with HLA and PTPN22 locus
SNPs dominating association at the genome-wide level.[1–3] The
Arg620Trp variant, encoded by SNP rs2476601 (C.T), of the
protein tyrosine phosphatase-22 (PTPN22) gene, is a prominent
determinant of some autoimmune phenotypes, including RA.
Strong association of the Trp620 variant has been repeatedly
demonstrated to RA, type 1 diabetes (T1D), Graves’ disease (GD)
and systemic lupus erythematosus (SLE) in European popula-
tions.[4] The Trp620 allele is very rare in Asian populations.[5]
The Trp620 effect seems to be restricted to autoimmune
phenotypes in which a defined auto-reactivity is evidenced by
specific autoantibodies. The LYP protein is part of a complex
down-regulating signal from the activated T-cell receptor (TCR),
with biochemical studies suggesting that PTPN22 inhibits T-cell
activation through dephosphorylation of the LCK and ZAP-70
kinases.[6] The Trp
620 allotype of LYP is unable to interact with
CSK, and generates a more active phosphatase that is more
effective in inhibiting TCR signalling than the Arg
620 allotype.[7]
In the thymus this might result in the positive selection of
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periphery, reduced TCR signalling in T-regulatory cells resulting
in reduced regulation of autoreactive T-cells. The Trp
620 allotype
also impairs signalling from the B-cell receptor.[8]
The PTPN22 gene maps to chromosome 1p13.2 within a
haplotype block of conserved linkage disequilibrium (LD) spanning
over 300 kb.[1] To investigate the possibility that further genetic
variants within PTPN22 have a role in RA, coding regions within
the gene were resequenced in USA people of white ethnic group-
European ancestry and ten common haplotypes were tested for
association with RA.[9] This analysis confirmed the predominant
role in disease susceptibility conferred by the haplotype tagged by
the Trp620 allele (minor allele of rs2476601: C.T) (haplotype ‘2’).
The analysis also provided evidence for a second haplotype that
increases risk of RA (haplotype ‘4’) independent of the Arg620Trp
variant. However this effect was not replicated in Norwegian,
Dutch or UK sample sets.[10–12] Interestingly, some variants in
PTPN22 provided evidence for a protective association with RA. A
haplotype uniquely defined by SNP rs12760457 was associated
with protection from RA (haplotype ‘5’),[9] although this
association was not replicated in UK and Dutch RA sample
sets.[10,11] Whilst this association was evident in T1D, it was not
independent of the Arg620Trp effect.[13] In RA, analysis of inter-
marker LD and extent of association of SNPs within the extended
PTPN22 haplotype block in a GWA scan of pooled genomic DNA
samples from New Zealand and the UK suggested the presence of
a second susceptibility determinant that was not explained by LD
with the Trp620 variant, and perhaps related to the protective
‘haplotype 5’ identified by Carlton et al.[1,9] Collectively the
previous reports [1,9] provided evidence for a second (protective)
common RA risk allele or haplotype within the PTPN22 locus, that
may map outside of the PTPN22 gene. Indeed association of a
rare functional PTPN22 variant (Arg263Gln, rs33996649:G.A,
minor allele frequency =2.6% in Caucasian) with SLE and RA
has been reported, with the A allele conferring a protective effect
independent of rs2476601.[14,15]
Here, our aim was to further investigate the possibility of allelic
heterogeneity at PTPN22 in RA, focusing on the possibility of the
existence of a common RA-protective haplotype independent of
Arg620Trp. Here, despite replicating the protective association of
haplotype ‘5’ with RA, there was no evidence that this association
was independent of rs2477601.
Results
The study of Carlton et al [9] first reported association of
haplotype ‘5’ with RA (P=1.5610
25) in 1122 cases and 1767
controls. In an attempt to replicate the association of haplotype 5
with RA, a haplotype 5-defining SNP (rs3789607) was genotyped
over the separate NZ and UK (London) RA case-control sample
sets (Table 1). These data were combined with that of Wesoly et al
[11] and with imputed data from the publically-available
Wellcome Trust Case Control Consortium (WTCCC) RA
genome-wide association (GWA) scan sample set.[2] The data of
Hinks et al [10] were not used as they overlap with that of the
WTCCC. The combined analysis of the UK, Dutch and NZ data
provided independent evidence supporting protective association
of haplotype 5 with RA (M-H pooled OR=0.91 [0.85–0.98],
P=0.016).
Given some evidence for an RA protective effect conferred by
haplotype 6 in the Carlton et al [9] sample sets (P=0.15 in sample
set 1; P=5 610
25 in sample set 2; combined one-tailed P by
Fisher’s method ,0.0001), we further investigated this finding in
the NZ, UK (London) and WTCCC cohorts. Haplotypes 6–10
can be distinguished from haplotypes 1–5 by rs1217414.[9] Four
Table 1. Analysis of association of PTPN22 ‘haplotype 5’ (rs3789607:T .C) with rheumatoid arthritis.
Genotype
1
Cohort T/T T/C C/C C Allele
2 OR [95% CI]
4 Allelic P
Carlton Set 1 257 (0.552)
189 (0.408)
173 (0.371)
220 (0.475)
36 (0.077)
54 (0.117)
245 (0.263)
328 (0.354)
0.65 [0.53–0.79] 2610
25
Carlton Set 2 350 (0.534)
659 (0.505)
274 (0.418)
512 (0.393)
32 (0.049)
133 (0.102)
338 (0.258)
778 (0.298)
0.82 [0.70–0.95] 0.008
Combined Carlton 607 (0.541)
848 (0.480)
447 (0.398)
732 (0.414)
68 (0.061)
187 (0.106)
583 (0.260)
1106 (0.313)
0.77 [0.68–0.87] 1.5610
25
Wesoly 357 (0.536)
148 (0.523)
269 (0.404)
119 (0.421)
40 (0.060)
16 (0.056)
349 (0.262)
151 (0.267)
0.98 [0.78–1.23] 0.83
WTCCC
3 933 (0.502)
1434 (0.488)
789 (0.424)
1253 (0.426)
138 (0.074)
251 (0.085)
1065 (0.286)
1755 (0.299)
0.94 [0.86–1.03] 0.19
NZ 452 (0.526)
263 (0.466)
344 (0.400)
248 (0.440)
64 (0.074)
53 (0.094)
472 (0.274)
354 (0.314)
0.83 [0.70–0.97] 0.023
UK London 129 (0.549)
86 (0.521)
94 (0.400)
64 (0.388)
12 (0.051)
15 (0.091)
118 (0.251)
94 (0.285)
0.84 [0.61–1.16] 0.29
Combined other 1871 (0.517)
1931 (0.487)
1496 (0.413)
1684 (0.427)
254 (0.070)
335 (0.085)
2004 (0.277)
2354 (0.298)
0.90 [0.84–0.97] 0.003
TOTAL 2478 (0.523)
2779 (0.486)
1943 (0.410)
2416 (0.423)
322 (0.068)
522 (0.091)
2587 (0.273)
3460 (0.303)
0.86 [0.81–0.92] 1.7610
26
1 Cases top line, controls bottom line. The Carlton Set 2 cases and controls, the combined other cases and total cases deviated mildly from HWE (P=0.02, 0.03, 0.05 and
0.02, respectively).
2 Allele 2; number of chromosomes (frequency).
3 Genotype data from rs17274634 were used (r
2=1 with rs3789607 in CEPH CEU (www.hapmap.org)).
4 The Mantel-Haenszel pooled OR=0.87 [0.82–0.93], P=7.5610
26; Breslow-Day test for heterogeneity P=0.083. The Mantel-Haenszel pooled OR excluding Carlton et al
data was 0.91 [0.85–0.98], P=0.016; Breslow-Day P=0.50.
doi:10.1371/journal.pone.0013544.t001
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HapMap (www.hapmap.org; release 23a), are required to
distinguish haplotype 6 from haplotypes 7–10, meaning it would
not be possible to use imputation to test these SNPs for association
in the WTCCC data. Instead we used rs12144309 to investigate
further association of the haplotype 6–10 group with RA -
rs12144309, which maps outside of the region studied by Carlton
et al [9], identifies one major haplotype within the 6–10 group
(Figure 1). In the CEU samples, rs12144309 tagged one haplotype
of frequency 14.2%, with the remaining 6–10 haplotypes
constituting 5.8%. rs12144309 was tested for association with
RA in the WTCCC dataset by use of the publically-available
imputation data, and by genotyping across the NZ and UK
(London) sample sets (Table 2). The resultant data (M-H pooled
OR=0.90 [0.82–0.98], P=0.021) confirmed association of a
protective haplotype within the haplotype 6–10 group with RA.
However it is not possible in this case to ascribe this association to
the same haplotype identified by Carlton et al. (haplotype 6).[9]
These data were unable to be combined with that of Wesoly et al
[11]; however, in their sample P for association of haplotype 6 with
RA was 0.48 (frequency of 10.7% in cases, 11.9% in controls).
Carlton et al [9] reported positive association of haplotype ‘4’
(tagged by rs3811021) with RA (combined OR=1.20, P=0.009).
We genotyped this SNP in the NZ and UK London cohorts and
analysed association with RA, with the inclusion of data from the
WTCCC [2], Wesoly et al [11] and Viken et al [12] studies
(Table 3). Meta-analysis by the Mantel-Haenszel method of all
the available data demonstrated heterogeneity (Breslow-Day
P,0.001; OR =0.85 [0.72–1.01], P=0.071), with separate
analysis after exclusion of the Carlton et al [9] data demonstrating
a protective effect mediated by haplotype ‘4’ in the sample sets
combined here (Breslow-Day P=0.12; M-H OR=0.85 [0.78–
0.91], P=1.4610
25).
Thus, within the PTPN22 gene there was replicated evidence
for two protective effects, as defined by haplotype 5 and within the
haplotype 6–10 group, and the protective effect we observed from
haplotype 4. Analysis of association at the three tagging SNPs
(rs3789607, rs3811021 and rs12144309) conditional on genotype at
rs2476601 in the combined WTCCC and NZ samples, revealed
no evidence for association with RA at any of the SNPs
independent of rs2476601 (all P.0.05). Haplotypes 4,5 and 6–
10 are unrelated to each other over the physical boundaries of the
PTPN22 gene [9] (Figure 1), and all contain Arg620. We invoked
an alternative explanation to account for the observed protective
effects in RA observed by us and Carlton et al [9]; that the
protective effects are caused by a single allele in the PTPN22
haplotype block, but outside of the region encompassing PTPN22
that was assessed by Carlton et al [9] (Figure 1), and not due to the
Arg620 allele. The LD relationship of haplotypes 4, 5 and 6–10
with markers in the extended PTPN22 haplotype block was
examined; all these haplotypes coalesce with the major allele of a
group of markers exhibiting very strong inter-marker LD (Figure 1;
r
2.0.90; rs12566340, rs7529353, rs11102691). These markers all
map within the 39 untranslated region (UTR) of the BFK (B-cell
lymphoma 2 (BCL2) family kin) gene (C1orf178). We hypothesized
that this group of markers was responsible for the protective effects
of haplotypes 4, 5 and 6–10 within the PTPN22 region.
Rs12566340 was genotyped in the NZ RA sample set and
imputed in the WTCCC RA sample set. Conditional analysis
revealed weak evidence for association of rs12566340 independent
of rs2476601 in the separate NZ and WTCCC datasets (P=0.036
and 0.033, respectively). Two-marker rs2476601-rs12566340
haplotypes were then estimated. In the NZ sample set comparison
of the risk conferred by the C-C haplotype to that conferred by the
C-T haplotype (both haplotypes contain the major allele at
rs2476601) suggested a marginal protective effect independent of
rs2476601 (OR=0.79, P=0.05). However this effect was not
replicated in the WTCCC sample set (OR=1.13, P=0.06)
(Table 4). Consistent with this, conditional analysis on the
combined NZ/WTCCC dataset did not support association of
rs12566340 independent of rs2476601 (P=0.76).
Previously .150 SNPs in the PTPN22 haplotype block and
flanking 400 kb were genotyped in a British T1D case-control
sample set with the aim of identifying putative T1D risk variants
independent of rs2476601 [13]. There was no evidence for allelic
heterogeneity, with rs2476601 remaining the best candidate for
sole causal variant. However, none of the SNPs rs12566340,
rs7529353 or rs11102691 was included in this analysis. We,
therefore, genotyped rs12566340 over the same T1D samples
previously studied by Smyth et al [13], with no evidence for an
effect at rs12566340 independent of rs2476601 (P=0.85). Equality
of risk conferred by the C-C haplotype in comparison to the C-T
Figure 1. Haplotype structure of structure of a portion of the PTPN22 haplotype block. The figure was generated by Haploview using
Phase 2 CEPH CEU HapMap data downloaded from www.hapmap.org, with the boundaries being rs4145859 (114.312 Mb) and rs10745340 (114.437
Mb).
doi:10.1371/journal.pone.0013544.g001
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OR=1.01 [0.94–1.09], P=0.78), consistent with the absence of
common allelic heterogeneity at PTPN22 in T1D.
We also examined the rare T-C haplotype of rs2476601-
rs12566340, testing for an effect on disease risk using the T-T
haplotype as reference. In T1D there was evidence for an
independent protective effect of the C allele (OR T-C=0.48
[0.29–0.80], P=0.004), but not in the combined NZ/WTCCC
RA dataset (OR T-C=1.43 [0.57–3.60]), P=0.45).
Recently Steck et al [16] published evidence for a 6-marker
protective haplotype in T1D, defined by markers in C1orf178,
from a case versus control analysis of chromosomes containing
only the Arg620 allele. The haplotype was tagged by the minor
allele of rs1539438 (A.G), which had been genotyped by Smyth et
al [13] and its association with T1D shown to be dependent on
rs2476601. We genotyped rs1539438 in the NZ RA sample set
and tested for association independent of rs2476601 in the NZ
samples, and in the publically-available WTCCC samples, with no
evidence for independent association detected (P=0.42 and 0.25,
respectively).
Discussion
The Trp620 allele (rs2476601) of the PTPN22 SNP rs2476601 is
strongly associated with both RA and T1D.[4,13] Smyth et al [13]
demonstrated that this allele explains the association of the
PTPN22 locus with T1D. They analysed 46 PTPN22 SNPs, and
111 further SNPs from the PTPN22 haplotype block and 400 kb
Table 2. Analysis of association of PTPN22 ‘haplotype 6–10’ group (rs12144309:C .T) with rheumatoid arthritis.
Genotype
1
Cohort C/C C/T T/T T Allele
3 OR [95% CI]
2 Allelic P
WTCCC
2 1230 (0.662)
1857 (0.633)
558 (0.300)
958 (0.326)
70 (0.038)
120 (0.041)
698 (0.188)
1198 (0.204)
0.90 [0.81–1.00] 0.052
NZ 612 (0.715)
387 (0.689)
231 (0.270)
168 (0.299)
13 (0.015)
7 (0.012)
257 (0.150)
182 (0.162)
0.91 [0.74–1.12] 0.40
UK London 172 (0.720)
114 (0.667)
60 (0.251)
52 (0.304)
7 (0.029)
5 (0.029)
74 (0.155)
62 (0.181)
0.83 [0.57–1.20] 0.31
TOTAL 2014 (0.682)
2358 (0.643)
849 (0.288)
1178 (0.321)
90 (0.030)
132 (0.036)
1029 (0.174)
1422 (0.194)
0.88 [0.80–0.96] 0.004
1. Cases top line, controls bottom line. The NZ controls deviated mildly from HWE (P=0.02).
2. Imputed genotypes were taken from www.wtccc.org.uk.
3. The Mantel-Haenszel combined OR=0.90 [0.82–0.98], P=0.021. The Breslow-Day test for heterogeneity P=0.90.
doi:10.1371/journal.pone.0013544.t002
Table 3. Analysis of association of PTPN22 ‘haplotype 4’ (rs3811021:A .G) with rheumatoid arthritis.
Genotype
1
Cohort A/A A/G G/G G Allele OR [95% CI]
3 Allelic P
Carlton Set 1 287 (0.619)
323 (0.699)
162 (0.349)
128 (0.277)
15 (0.032)
11 (0.024)
192 (0.207)
150 (0.162)
1.35 [1.06–1.70] 0.014
Carlton Set 2 425 (0.645)
883 (0.670)
197 (0.299)
383 (0.291)
37 (0.056)
51 (0.039)
271 (0.206)
485 (0.184)
1.15 [0.97–1.35] 0.11
Combined Carlton 712 (0.634)
1206 (0.678)
359 (0.320)
511 (0.287)
52 (0.046)
62 (0.035)
463 (0.206)
635 (0.178)
1.20 [1.05–1.37] 8.8610
23
Wesoly 461 (0.693)
177 (0.623)
188 (0.283)
97 (0.341)
16 (0.024)
10 (0.035)
220 (0.165)
117 (0.206)
0.76 [0.59–0.99] 0.034
Viken 563 (0.657)
337 (0.609)
261 (0.305)
187 (0.338)
33 (0.039)
29 (0.052)
327 (0.191)
245 (0.222)
0.83 [0.69–1.00] 0.047
WTCCC
2 1244 (0.669)
1900 (0.648)
558 (0.300)
917 (0.313)
57 (0.031)
117 (0.040)
672 (0.181)
1151 (0.196)
0.90 [0.81–1.01] 0.061
NZ 645 (0.752)
389 (0.697)
201 (0.234)
159 (0.285)
12 (0.014)
10 (0.018)
225 (0.131)
179 (0.160)
0.79 [0.63–0.97] 0.030
UK London 179 (0.810)
105 (0.691)
42 (0.190)
43 (0.283)
0 (0.000)
4 (0.026)
42 (0.095)
51 (0.168)
0.52 [0.34–0.81] 0.003
Combined other 3092 (0.693)
2908 (0.649)
1250 (0.280)
1403 (0.313)
118 (0.026)
170 (0.038)
1486 (0.167)
1743 (0.194)
0.83 [0.77–0.89] 1.2610
26
TOTAL 3804 (0.681)
4114 (0.657)
1609 (0.288)
1914 (0.306)
170 (0.030)
232 (0.037)
1949 (0.175)
2378 (0.190)
0.90 [0.84–0.96] 2.2610
23
1 Cases top line, controls bottom line.
2 Imputed genotypes were taken from www.wtccc.org.uk.
3 The Mantel-Haenszel combined OR =0.85 [0.72–1.01], P=0.071. The Breslow-Day test for heterogeneity P,0.001.
doi:10.1371/journal.pone.0013544.t003
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that taken by Smyth et al [13], being driven by the findings of
Carlton et al [9], beginning with studying the specific haplotypes
that they reported that altered RA risk (haplotypes 4, 5 and 6–10).
By generation of new data, and meta-analysis, we also found that
these haplotypes influence the risk of RA, although with an
opposing direction of effect in the case of haplotype 4. However,
neither the haplotype-defining SNPs, nor rs12566340 (haplotypes
4, 5, 6–10 converge to the major allele), were independently
associated with RA. There was also no evidence for independent
association of this SNP with T1D (neither rs12566340, nor any
surrogate SNPs had previously been analysed by Smyth et al [13]).
We conclude that it is unlikely that allelic heterogeneity at the
PTPN22 locus, driven by common variants, exists in RA. The
published functional data [7], including correlations between TCR
signalling and carriage of the different alleles of Arg620Trp
strongly supports that this non-synonymous SNP is the causal
variant. However, given the entire LD region has not yet been
resequenced, there is still a possibility that as yet unidentified
variant(s) could play a role in disease etiology.
It is important to note that our approach examined common
Arg620Trp-independent variants. We did not address the question
of whether or not there are rare Arg620Trp-independent variants,
which are known to exist, in RA and SLE at least
(Arg263Gln).[14,15] There was evidence for inequality of risk
for the rare T-C haplotype compared to the T-T haplotype in
T1D, but this was not supported in the RA sample set. Further
study of this rare haplotype will be difficult, owing to its scarcity.
The 263Gln allele, which confers a protective effect in RA
independent of Arg620Trp,[15] is nearly exclusively contained on
haplotypes containing the major (620Arg) allele at rs2476601 in
Caucasians,[15] meaning it cannot explain any possible indepen-
dent protective effect of the T-C haplotype.
Carlton et al [9] concluded that the Arg620Trp variant did not
fully explain the association between PTPN22 and RA. Using a
haplotype method of analysis and conditional logistical regression
they concluded that haplotype ‘4’ (tagged by the G allele of
rs3811021) was primarily responsible for their observation that
Arg620Trpdidnot fullyexplain the associationofthePTPN22locus
with RA. By testing for equality of risk between haplotypes
containing rs2476601 and rs12566340, we found no evidence for an
RA risk effect independent of rs2476601, nor for any of the
haplotype 4, 5 and 6–10 tagging SNPs. Our apparently conflicting
findings need to be considered in light of the heterogeneity in
association with RA of haplotype 4 between the USA European-
ancestry samples studied by Carlton et al [9] (susceptible effect), and
the British and European samples studied here (protective effect;
note that the European population of NZ is predominantly derived
from immigrants from Britain and Europe). Acknowledging that
different statistical methods were used, it is possible that population-
specific effects are obscuring investigation of an Arg620Trp-
independent effect on RA risk at the PTPN22 locus. Certainly the
LD between the haplotype ‘4’ and ‘5’-defining SNPs differs between
the samples studied by Carlton et al [9] (r
2,0.4 [9]) and the
WTCCC and HapMap CEU samples (r
2,0.1). It is unlikely that
the difference in haplotype 4 results is caused by fluctuation in
control frequencies, as was previously noted with respect to
observation of a protective haplotype in a study of the PTPN22
locus in Graves’ disease [13,17] – changes in both the control and
case rs3811201 frequencies areevident between the Carlton et al [9]
and the newly analysed data (Table 3). Genotyping of rs3811021,
rs12566340, rs2476601, rs3789607 and other relevant SNPs over
additional USA and British/European sample sets is warranted.
The possibility of clinical heterogeneity between sample sets playing
a role in the different outcomes of our and the Carlton et al studies
should also not be overlooked. However, it is not possible to
comprehensively consider this possibility presently, owing to the
paucity of clinical data available for the relevant RA sample sets
(refer to Samples and Methods and Carlton et al [9]).
Methods
Ethical Statement
Ethical approval for the NZ study was given by the MultiRegion
and Lower South Ethics Committees, the UK London RA study
by the Lewisham Hospital and Guy’s and St. Thomas’ Hospitals
local research ethics committees, participants with T1D were
enrolled under study protocols approved by the Institutional
Review Board of each UK institution that contributed (see http://
www.childhood-diabetes.org.uk/grid.shtml), and 1958 birth co-
hort controls for the T1D comparison by the London Multiregion
Ethics Committee. All subjects gave written informed consent, or
their parents/guardian for those considered too young to consent.
Study subjects
Data from four separate RA case-control sample sets, all
consisting of white European subjects, were analysed. All cases
satisfied the 1987 American College of Rheumatology criteria for
RA.[18]
1. The New Zealand (NZ) sample sets consisted of 860 RA
patients and 564 controls. Cases were recruited from outpatient
clinics in Auckland, Bay of Plenty, Wellington, Canterbury,
Otago and Southland. Twenty-eight percent were male and
72% female. Of the RA patients for whom serologic data were
available, 82% (571/697) were rheumatoid factor (RF) positive
and 65% (303/465) were anti-cyclic citrullinated peptide (CCP)
antibody positive. The NZ control samples (n=557) consisted
of healthy subjects recruited from Otago and Auckland.
2. The UK Wellcome Trust Case Control Consortium (WTCCC)
patient group consisted of 1860 European individuals, of which
Table 4. Rs2476601-rs12566340 haplotypic analysis.
Haplotype Case (N, freq) Cont (N, freq) OR [95% CI] P
RA
1
C-C 1225 (0.716)
2550 (0.721)
3775 (0.719)
877 (0.784)
4323 (0.771)
5200 (0.773)
0.79 [0.63–1.00]
1.13 [0.99–1.30]
1.02 [0.91–1.14]
0.048
0.063
0.743
C-T 238 (0.139)
381 (0.108)
619 (0.118)
135 (0.121)
733 (0.131)
868 (0.129)
1.00 (reference)
1.00 (reference)
1.00 (reference)
-
-
-
T-C 12 (0.007)
1 (0.000)
13 (0.002)
1 (0.001)
6 (0.001)
7 (0.001)
-
-
-
-
-
-
T-T 237 (0.139)
606 (0.171)
844 (0.161)
105 (0.094)
544 (0.097)
649 (0.097)
-
-
-
-
-
-
T1D
C-C 10287 (0.707) 10831 (0.776) 1.01 [0.94-1.09] 0.78
C-T 1685 (0.116) 1800 (0.129) 1.00 (reference) -
T-C 35 (0.002) 36 (0.003) - -
T-T 2539 (0.175) 1289 (0.092) - -
1. Within each cell in the RA half, NZ data are top, WTCCC data middle and
combined bottom.
doi:10.1371/journal.pone.0013544.t004
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Caucasian individuals with a median age between 40–49 years,
of whom 49% were male.[2]
3. The UK London sample set consisted of 235 RA patients
recruited at Lewisham, and Guy’s and St. Thomas’s Hospitals, of
whom 79.3% were female and 63.1% RF positive. 165 UK
control samples were purchased from the European Collection of
Cell Cultures (www.hpacultures.org.uk/collections/ecacc.jsp).
4. Published data from two sample sets were used. The Dutch
sample setconsisted of 667 cases and 286 controlsrecruited from
Leiden[11] and the Norwegian sample set consisted of 861 cases
and 559 controls recruited from Oslo[12]. Demographic and
clinical data were not presented for either set of samples.
In T1D, 7,273 cases and 6,978 controls were genotyped for
rs2476601 and rs12566340. The affected individuals were
recruited as part of the Juvenile Diabetes Research Foundation/
Wellcome Trust Diabetes and Inflammation Laboratory’s British
case collection. Most individuals with T1D were ,16 years of age
at the time of collection (mean age at diagnosis 7.5 years, range 0.5
to 16 years) and all resided in Britain. The control samples were
obtained from the British 1958 Birth cohort, an ongoing study of
all people born in Great Britain during one week in 1958. All cases
and controls were of self-reported white ethnic group and
European ancestry.
Genotyping and imputation
Subjects from the NZ and UK London sample sets were
genotyped in this study using PCR-RFLP: rs3789607 using
primers GGCTGTTTTATTTCCCCTGT and GAGCTAGTT-
TGCTATCACTG that result in cleavage of the 160 bp product
into 100/60 bp fragments using aTaqI; rs12566340 using primers
TGATCAATCTGATGGCAGTATATAGGACAA and CCTC-
AGTCATTTTTACCTTG that result in cleavage of the 210 bp
product into 179/31 bp fragments using Tsp509I; and rs12144309
using primers ATGGCACCTCAGATGCATTA and AGTATT-
TACATATTTAATCCACCTGGAATC that result in cleavage
of the 176 bp product in 145/31 bp fragments using aTaqI.
rs1539438 was genotyped over the NZ samples by Taqman
(Applied Biosystems) using probe C_1900118_10 and primers
GTAATTTTATTAAGAAATACTTCCT[C/T] and GACTT-
CTTAGGTCCTGCACATGGTA.
Subjects from the T1D sample set were genotyped with
TaqMan, which was carried out in accordance with the
manufacturers’ protocols. All genotyping data were scored blind
to case-control status; TaqMan genotyping was double scored by a
second operator to minimize error.
Access to genotype data was granted by the WTCCC (www.
wtccc.org.uk). Genotypes for rs12144309 and rs12566340 were
imputed using IMPUTE v0.2.0[19] with default parameters, a
10 Mb window centred on the PTPN22 locus and called using a
quality threshold of 0.9.
Data analysis
All genotype data were checked for deviation from Hardy-
Weinberg equilibrium using http://ihg.gsf.de/cgi-bin/hw/hwa1.
pl. The NZ control samples exhibited a small deviation from
Hardy-Weinberg equilibrium (HWE) for markers rs12566340 and
rs12144309 (P=0.009 and 0.02, respectively). 20% of genotypes
for each of rs12566340 and rs12143309 were consequently
repeated, with 100% concordance for both. SHEsis [20] was used
to generate basic summary statistics (allelic and genotypic P values
by Fisher’s chi-square, testing for deviation from HWE).
UNPHASED[21] was used to test for equality of risks between
haplotypes and to test for association at one marker conditional
upon a second. STATA 8.0 was used to calculate Mantel-
Haenszel (M-H) pooled ORs and test for heterogeneity between
datasets, using a fixed effects model in the absence, and a random
effects model in the presence, of heterogeneity. The power to
detect a putative independent causal effect of weak magnitude
(OR=1.2/0.83, alpha=0.01) owing to rs12566340 was 97% for
RA and 100% for T1D.
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